<p>Spyre Therapeutics, Inc. (NASDAQ:SYRE - 獲取免費報告) 的股價在週二創下 52 周新低。該公司股價最低交易至 20.25 美元，最後交易價為 20.09 美元，成交量為 133465 股。該股票此前收盤價為 21.26 美元。</p>
<p>獲取 <strong>Spyre Therapeutics</strong> 的提醒：</p>
<h2>華爾街分析師觀點</h2>
<p>多位分析師最近對 SYRE 股票發表了評論。羅伯特·W·貝爾德將 Spyre Therapeutics 的目標價從 50.00 美元上調至 65.00 美元，並在 11 月 13 日的報告中給予該股票 “跑贏大盤” 的評級。高盛集團在 2 月 18 日的研究報告中將 Spyre Therapeutics 的評級上調至 “強力買入”。最後，Wedbush 在 1 月 13 日的研究報告中重申了 “跑贏大盤” 的評級，並對 Spyre Therapeutics 的股票設定了 65.00 美元的目標價。七位股票研究分析師對該股票給予了買入評級，一位分析師給予了強力買入評級。根據 MarketBeat.com 的數據，Spyre Therapeutics 目前的共識評級為 “買入”，平均目標價為 54.83 美元。</p>
<p><strong>查看我們關於 SYRE 的最新報告</strong></p>
<h2>Spyre Therapeutics 股價下跌 4.2%</h2>
<p>該公司的 50 日移動平均線為 22.72 美元，200 日移動平均線為 26.97 美元。該公司的市值為 10.5 億美元，市盈率為-2.72，貝塔值為 2.85。</p>
<h2>機構投資者對 Spyre Therapeutics 的看法</h2>
<p>多家對沖基金最近買入和賣出了 SYRE 的股票。Driehaus Capital Management LLC 在第四季度將其在 Spyre Therapeutics 的股份增加了 308.1%。Driehaus Capital Management LLC 目前擁有 2803655 股該公司的股票，價值 65269000 美元，此前在上個季度增持了 2116575 股。FMR LLC 在第四季度將其在 Spyre Therapeutics 的持倉增加了 15.4%。FMR LLC 目前擁有 8801266 股該公司的股票，價值 204893000 美元，此前在上個季度增持了 1177385 股。Jefferies Financial Group Inc.在第四季度將其在 Spyre Therapeutics 的持股增加了 167.6%。Jefferies Financial Group Inc.目前擁有 1216954 股該公司的股票，價值 28331000 美元，此前在上個季度增持了 762147 股。Wellington Management Group LLP 在第三季度將其在 Spyre Therapeutics 的持股增加了 89.4%。Wellington Management Group LLP 目前擁有 1507200 股該公司的股票，價值 44327000 美元，此前在上個季度增持了 711254 股。最後，Boxer Capital Management LLC 在第四季度購買了 Spyre Therapeutics 的新頭寸，價值 10864000 美元。目前 80.39% 的股票由機構投資者持有。</p>
<h2>Spyre Therapeutics 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>Spyre Therapeutics, Inc.是一家處於臨牀前階段的生物技術公司，專注於為患有炎症性腸病（IBD）的患者開發治療方案。它開發的 SPY001 是一種人源單克隆免疫球蛋白 G1 抗體，旨在選擇性結合 a4ß7 整合素，正在開發用於治療 IBD（潰瘍性結腸炎和克羅恩病）。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Spyre Therapeutics</li>
<li>如何利用高貝塔股票最大化投資收益</li>
<li>NVIDIA 股票：科技動盪時期的市場晴雨表</li>
<li>銀行股票 - 最值得投資的銀行股票</li>
<li>Palantir 股票接近熊市區域 - 原因及下一步？</li>
<li>如何有效使用 MarketBeat 評級篩選器</li>
<li>家得寶迎來轉機：今年可能創下新高</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 Spyre Therapeutics 嗎？</h2>
<p>在考慮 Spyre Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 Spyre Therapeutics 並不在名單上。</p>
<p>雖然 Spyre Therapeutics 目前在分析師中獲得了 “買入” 評級，但頂級分析師認為這五隻股票更值得買入。</p>
<p>在這裏查看這五隻股票</p>

SYRE

<p>Spyre Therapeutics（納斯達克代碼：SYRE）創下 52 周新低，報 20.09 美元，較前一交易日收盤價 21.26 美元下跌。分析師意見不一，羅伯特·W·貝爾德將其目標價上調至 65.00 美元，並維持 “跑贏大盤” 評級。高盛將其評級上調至 “強力買入”。機構投資者持有該股票的 80.39%，Driehaus Capital 和 FMR LLC 的持股比例顯著增加。該公司專注於開發針對炎症性腸病（IBD）的治療藥物</p>

<p>Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report)'s stock price hit a new 52-week low on Tuesday . The company traded as low as $20.25 and last traded at $20.09, with a volume of 133465 shares traded. The stock had previously closed at $21.26.</p>
<div class="lb-trans"><p>Spyre Therapeutics, Inc. (NASDAQ:SYRE - 獲取免費報告) 的股價在週二創下 52 周新低。該公司股價最低交易至 20.25 美元，最後交易價為 20.09 美元，成交量為 133465 股。該股票此前收盤價為 21.26 美元。</p>
</div><p>Get <strong>Spyre Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Spyre Therapeutics</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>A number of analysts recently commented on SYRE shares. Robert W. Baird lifted their price target on Spyre Therapeutics from $50.00 to $65.00 and gave the stock an &#34;outperform&#34; rating in a report on Wednesday, November 13th. The Goldman Sachs Group raised Spyre Therapeutics to a &#34;strong-buy&#34; rating in a research note on Tuesday, February 18th. Finally, Wedbush restated an &#34;outperform&#34; rating and issued a $65.00 price target on shares of Spyre Therapeutics in a research note on Monday, January 13th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Spyre Therapeutics presently has a consensus rating of &#34;Buy&#34; and an average target price of $54.83.</p>
<div class="lb-trans"><p>多位分析師最近對 SYRE 股票發表了評論。羅伯特·W·貝爾德將 Spyre Therapeutics 的目標價從 50.00 美元上調至 65.00 美元，並在 11 月 13 日的報告中給予該股票 “跑贏大盤” 的評級。高盛集團在 2 月 18 日的研究報告中將 Spyre Therapeutics 的評級上調至 “強力買入”。最後，Wedbush 在 1 月 13 日的研究報告中重申了 “跑贏大盤” 的評級，並對 Spyre Therapeutics 的股票設定了 65.00 美元的目標價。七位股票研究分析師對該股票給予了買入評級，一位分析師給予了強力買入評級。根據 MarketBeat.com 的數據，Spyre Therapeutics 目前的共識評級為 “買入”，平均目標價為 54.83 美元。</p>
</div><p><strong>View Our Latest Report on SYRE</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 SYRE 的最新報告</strong></p>
</div><h2>Spyre Therapeutics Trading Down 4.2 %</h2>
<div class="lb-trans"><h2>Spyre Therapeutics 股價下跌 4.2%</h2>
</div><p>The company has a 50-day moving average of $22.72 and a 200-day moving average of $26.97. The firm has a market capitalization of $1.05 billion, a price-to-earnings ratio of -2.72 and a beta of 2.85.</p>
<div class="lb-trans"><p>該公司的 50 日移動平均線為 22.72 美元，200 日移動平均線為 26.97 美元。該公司的市值為 10.5 億美元，市盈率為-2.72，貝塔值為 2.85。</p>
</div><h2>Institutional Investors Weigh In On Spyre Therapeutics</h2>
<div class="lb-trans"><h2>機構投資者對 Spyre Therapeutics 的看法</h2>
</div><p>A number of hedge funds have recently bought and sold shares of SYRE. Driehaus Capital Management LLC increased its stake in shares of Spyre Therapeutics by 308.1% in the 4th quarter. Driehaus Capital Management LLC now owns 2,803,655 shares of the company's stock valued at $65,269,000 after acquiring an additional 2,116,575 shares during the last quarter. FMR LLC lifted its position in shares of Spyre Therapeutics by 15.4% during the 4th quarter. FMR LLC now owns 8,801,266 shares of the company's stock worth $204,893,000 after buying an additional 1,177,385 shares during the last quarter. Jefferies Financial Group Inc. increased its holdings in Spyre Therapeutics by 167.6% in the 4th quarter. Jefferies Financial Group Inc. now owns 1,216,954 shares of the company's stock worth $28,331,000 after purchasing an additional 762,147 shares in the last quarter. Wellington Management Group LLP raised its holdings in Spyre Therapeutics by 89.4% during the 3rd quarter. Wellington Management Group LLP now owns 1,507,200 shares of the company's stock worth $44,327,000 after purchasing an additional 711,254 shares during the last quarter. Finally, Boxer Capital Management LLC bought a new position in Spyre Therapeutics during the fourth quarter worth $10,864,000. 80.39% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>多家對沖基金最近買入和賣出了 SYRE 的股票。Driehaus Capital Management LLC 在第四季度將其在 Spyre Therapeutics 的股份增加了 308.1%。Driehaus Capital Management LLC 目前擁有 2803655 股該公司的股票，價值 65269000 美元，此前在上個季度增持了 2116575 股。FMR LLC 在第四季度將其在 Spyre Therapeutics 的持倉增加了 15.4%。FMR LLC 目前擁有 8801266 股該公司的股票，價值 204893000 美元，此前在上個季度增持了 1177385 股。Jefferies Financial Group Inc.在第四季度將其在 Spyre Therapeutics 的持股增加了 167.6%。Jefferies Financial Group Inc.目前擁有 1216954 股該公司的股票，價值 28331000 美元，此前在上個季度增持了 762147 股。Wellington Management Group LLP 在第三季度將其在 Spyre Therapeutics 的持股增加了 89.4%。Wellington Management Group LLP 目前擁有 1507200 股該公司的股票，價值 44327000 美元，此前在上個季度增持了 711254 股。最後，Boxer Capital Management LLC 在第四季度購買了 Spyre Therapeutics 的新頭寸，價值 10864000 美元。目前 80.39% 的股票由機構投資者持有。</p>
</div><h2>Spyre Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Spyre Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).</p>
<div class="lb-trans"><p>Spyre Therapeutics, Inc.是一家處於臨牀前階段的生物技術公司，專注於為患有炎症性腸病（IBD）的患者開發治療方案。它開發的 SPY001 是一種人源單克隆免疫球蛋白 G1 抗體，旨在選擇性結合 a4ß7 整合素，正在開發用於治療 IBD（潰瘍性結腸炎和克羅恩病）。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Spyre Therapeutics</li>
<li>How to Use High Beta Stocks to Maximize Your Investing Profits</li>
<li>NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times</li>
<li>Bank Stocks - Best Bank Stocks to Invest In</li>
<li>Palantir Stock Nears Bear Market Territory - Why and What’s Next?</li>
<li>How to Effectively Use the MarketBeat Ratings Screener</li>
<li>Home Depot Turns a Corner: New Highs Likely This Year</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Spyre Therapeutics</li>
<li>如何利用高貝塔股票最大化投資收益</li>
<li>NVIDIA 股票：科技動盪時期的市場晴雨表</li>
<li>銀行股票 - 最值得投資的銀行股票</li>
<li>Palantir 股票接近熊市區域 - 原因及下一步？</li>
<li>如何有效使用 MarketBeat 評級篩選器</li>
<li>家得寶迎來轉機：今年可能創下新高</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Spyre Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Spyre Therapeutics 嗎？</h2>
</div><p>Before you consider Spyre Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Spyre Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spyre Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 Spyre Therapeutics 並不在名單上。</p>
</div><p>While Spyre Therapeutics currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Spyre Therapeutics 目前在分析師中獲得了 “買入” 評級，但頂級分析師認為這五隻股票更值得買入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Spyre Therapeutics（納斯達克股票代碼：SYRE）創下一年新低 - 你應該賣出嗎？